Illumina Inc (ILMN)
Healthcare
Diagnostics & Research
205.10 $
Closing price · As of: 31. Jul 2026
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Illumina Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 15 of our scanner strategies — each hit links to the scanner.
Breakout & Setup
Momentum & Trend
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Basics
Market Cap
The value of the entire company on the market: share price times total shares outstanding.
31.0$B
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
151Mio.
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
97.8%
Beta
Volatility versus the overall market: 1 = moves like the market, 2 = twice as much, under 1 = calmer than the market.
1.5
Performance
Perf. 1M
Price performance over the last month.
14.10%
Perf. 3M
Price performance over the last 3 months.
53.90%
Perf. 6M
Price performance over the last 6 months.
33.80%
YTD Performance (%)
Price performance since the start of the year (Year to Date).
25.70%
52-Week-High Distance
How far the price sits below its highest point over the last 52 weeks. 0% means the stock is at its year high.
-2.8%
Valuation
P/E
Price-to-earnings ratio: how many years of profit does the stock cost? The lower, the cheaper the valuation. No earnings means no P/E.
37.0
Forward P/E
P/E based on expected earnings for the next 12 months instead of past earnings — analysts' bet on the future.
36.0
PEG
P/E divided by expected earnings growth: puts valuation in relation to growth. Around 1 is considered fair, well above that is pricey.
3.3
P/B
Price-to-book ratio: market value relative to book equity.
11.6
P/S
Price-to-sales ratio: market value divided by annual sales. Important for companies that aren't (yet) profitable.
6.9
EV/EBITDA
Enterprise value including debt (EV) relative to operating profit before depreciation and amortization (EBITDA) — more comparable than P/E because debt counts too. Extreme values arise when EBITDA is near zero.
20.9
Price/FCF
Market value divided by free cash flow: how many years of freely available cash does the stock cost? More honest than P/E because cash flow is harder to dress up.
33.0
Profitability
Gross Margin
Gross margin: what's left of sales after only direct production costs are deducted — the product's pricing power.
68.3%
EBIT Margin
EBIT margin: operating profit as a percentage of sales — the earning power of the core business before interest and taxes.
18.3%
Net Margin
Net margin: what's left of sales as profit after ALL costs, interest, and taxes.
19.4%
Return on Equity
Return on equity: how much profit does the company generate per year on shareholders' equity?
33.8%
Return on Assets
Return on assets: how much profit the company generates from its total assets (equity and debt combined).
8.7%
Balance Sheet & Safety
Equity Ratio
Equity ratio: equity as a share of total assets. The higher, the more resilient the balance sheet.
40.8%
Debt/Equity
Leverage ratio: financial debt divided by equity. Under 1 is generally seen as solid; negative values mean negative equity.
1.8
fortress balance sheet
Altman Z″
Edward Altman's bankruptcy early-warning score. We use the Z″ variant, built from four balance-sheet ratios — it is designed for service companies and non-manufacturers and uses book value instead of market value. On that scale: below 1.1 = danger zone, 2.6 and up = safe zone, in between a grey area. Because the classic Altman Z is calculated differently, the two numbers are not directly comparable. The formula does not fit banks, insurers, or real-estate stocks.
6.18
Piotroski
Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag.
5 out of 9
Growth
Sales Growth Last Quarter
Sales growth in the most recently reported quarter versus the same quarter a year ago (YoY).
4.80%
EPS Growth Last Quarter
Growth in earnings per share in the most recently reported quarter versus the same quarter a year ago (YoY).
6.10%
Sales Growth (Year)
Sales growth in the last fiscal year versus the year before.
-0.78%
Forward Sales Growth
Sales growth analysts expect over the next 12 months — an estimate, not a guarantee.
5.71%
Forward EPS Growth
Earnings-per-share growth analysts expect over the next 12 months — an estimate, not a guarantee.
13.40%
Quality & Screener
Stage
Weinstein phases 1 through 4: 1 = basing, 2 = uptrend (the only buy phase), 3 = topping, 4 = downtrend. Measured against the 30-week line.
2
RS Rating
Relative strength from 1 to 99: an RS of 95 means the stock has outperformed 95% of all stocks.
83
EPS Rating
Earnings growth rating from 1 to 99 versus all stocks — high values mean above-average earnings growth.
55
Piotroski
Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag.
5 out of 9
Fundamental Rating
Our own Fundamental Rating: 0 to 100 points with an A+ to F grade. 50 points is the average across the universe, 100 the best possible score. It scores growth, earnings surprises, analyst estimates, margins, cash flow, and balance-sheet safety — every stock percentile-ranked against all others. Grades: A+ from 95, A from 75, B from 55, C from 45, D from 25, E from 5, F below.
B (55 out of 100)
fortress balance sheet
Altman Z″
Edward Altman's bankruptcy early-warning score. We use the Z″ variant, built from four balance-sheet ratios — it is designed for service companies and non-manufacturers and uses book value instead of market value. On that scale: below 1.1 = danger zone, 2.6 and up = safe zone, in between a grey area. Because the classic Altman Z is calculated differently, the two numbers are not directly comparable. The formula does not fit banks, insurers, or real-estate stocks.
6.18
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 1.17 | – | 1,104 | -1.60 | 16.90 | 364 | 335 |
| 2025: Q1 | 0.82 | – | 1,041 | -3.30 | 12.60 | 240 | 201 |
| 2025: Q2 | 1.50 | – | 1,057 | -4.90 | 22.20 | 234 | 211 |
| 2025: Q3 | 0.97 | -77.90 | 1,083 | 0.30 | 13.90 | 284 | 260 |
| 2025: Q4 | 2.17 | 85.60 | 1,160 | 5.10 | 28.80 | 321 | 267 |
| 2026: Q1 | 0.87 | 5.60 | 1,091 | 4.80 | 12.30 | 289 | 251 |
| 2026: Q2 | 1.35 | -10.00 | 1,159 | 9.60 | 17.90 | 201 | 161 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Illumina, Inc. bietet sequenzierungs- und array-basierte Lösungen für die genetische und genomische Analyse in Nord- und Südamerika, Europa, Greater China, dem asiatisch-pazifischen Raum, dem Nahen Osten und Afrika an.
| Employees | 8,600 |
|---|---|
| Headquarters | San Diego, CA |
| Website | illumina.com |
| IPO Date | 28. Jul 2000 |
| Next Earnings | 30. Jul 2026 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Jacob Thaysen Ph.D. | CEO, Interim Chief Commercial Officer & Director | 1975 |
| Ankur Dhingra CPA | Chief Financial Officer | 1976 |
| Kevin Carl Pegels | Chief of Global Operations | 1968 |
| Steven Barnard Ph.D. | Chief Technology Officer | 1961 |
| Stephanie Campos | President | – |
| Scott Ericksen | VP & Chief Accounting Officer | 1973 |
| Mark Field | Chief Information Officer | 1971 |
| Conor Noel McNamara C.F.A. | VP of Investor Relations | – |
| Scott Davies | Chief Legal Officer & Secretary | 1970 |
| Jakob Wedel | Chief Strategy & Corporate Development Officer | 1972 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.